jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2013-5-3-35-38jofin-184Research ArticleОригинальные исследованияOriginal ResearchЭффективность противовирусной терапии рецидива хронического гепатита С у пациентов, перенесших трансплантацию печениEfficiency of Antiviral Therapy for Recurrence of Chronic Hepatitis C in Patients Undergoing Liver TransplantationСухорукА. А.SukhorukA. A.

очный аспирант кафедры инфекционных болезней взрослых и эпидемиологии Санкт-Петербургского государственного педиатрического медицинского университета; тел.: + 7-921-975-31-75

amaranta1981@mail.ruЭсауленкоЕ. В.EsaulenkoE. V.

заведующая кафедрой инфекционных болезней взрослых и эпидемиологии Санкт-Петербургского государственного педиатрического медицинского университета, д.м.н., профессор;тел.: +7-921-324-30-50

esaulenko@influenza.spb.ruЯковлевА. А.YakovlevA. A.

главный врач Клинической инфекционной больницы им. С.П. Боткина, д.м.н., профессор; тел.: 8(812)717-44-24

botkin_hosp@zdrav.spb.ruХомченкоИ. В.KhomchenkoI. V.

заведующая 29-м отделением Клинической инфекционной больницы им. С.П. Боткина, к.м.н.; тел.: +7-911-739-64-44

misskhomchenko@yandex.ruСанкт-Петербургский государственный педиатрический медицинский университет, Санкт-ПетербургРоссияSaint-Petersburg State Pediatric Medical University, Saint-PetersburgRussian FederationКлиническая инфекционная больница им. С.П. Боткина, Санкт-ПетербургРоссияClinical Infectious Diseases Hospital named after S.P. Botkin, Saint-PetersburgRussian Federation201316092014533538Copyright © Сухорук А.А., Эсауленко Е.В., Яковлев А.А., Хомченко И.В., 20142014Сухорук А.А., Эсауленко Е.В., Яковлев А.А., Хомченко И.В.Sukhoruk A.A., Esaulenko E.V., Yakovlev A.A., Khomchenko I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/184

В статье проанализирован собственный опыт наблюдения и лечения рецидива хронического гепатита С у пациентов после трансплантации печени. При выполнении операции на фоне активно текущей инфекции рецидив заболевания неизбежен, а прогрессия быстрее. Эффективность противовирусной терапии на фоне иммуносупрессии ниже, чем у имуннокомпетентных лиц. Частота непосредственного вирусологического ответа составила 55,5%. Устойчивый вирусологический ответ достигнут в 42,9% случаев. Треть пациентов из-за развившихся нежелательных явлений не смогли получить полный курс лечения.

In the article the analysis data of observation and treatment recurrence hepatits C after liver transplantation. When performing operations on the background of the current active infection relapse is inevitable, and progression is fast. The effectiveness of antiviral therapy for immunosuppression is low. End-of-treatment response was achieved in 55,5%. Sustained virologic response was achieved in 42.9%. In one-third cases treatment was discontinuation because of adverse events.

гепатит Странсплантация печенирецидивпротивовирусная терапияhepatitis Cliver transplantationrecurrenceantiviral therapyReferencesCiccorossi, P. Viral load 1week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C / P. Ciccorossi [et al.] // Liver International. – 2007. – V. 27, Issue 5. – P. 612–619.Ciccorossi, P. Viral load 1week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C / P. Ciccorossi [et al.] // Liver International. – 2007. – V. 27, Issue 5. – P. 612–619.Seeff, L.B. Natural history of chronic hepatitis C / L.B. Seeff // Hepatology. – 2002. – V. 36, Issue suppl. 1. – P. S35–S46.Seeff, L.B. Natural history of chronic hepatitis C / L.B. Seeff // Hepatology. – 2002. – V. 36, Issue suppl. 1. – P. S35–S46.Alcántar, R. B. Treatment of hepatitis C before and after liver transplantation / R.B Alcántar. // Annals of Hepatology. – 2006. – V. 5, Suppl. 1. – P. S63–S66.Alcántar, R. B. Treatment of hepatitis C before and after liver transplantation / R.B Alcántar. // Annals of Hepatology. – 2006. – V. 5, Suppl. 1. – P. S63–S66.Berenguer, M. Natural history of clinically compensated hepatitis C virus–related graft cirrhosis after liver transplantation / M. Berenguer [et al.] // Hepatology. – 2000. – V. 32, № 4. – P. 852–858.Berenguer, M. Natural history of clinically compensated hepatitis C virus–related graft cirrhosis after liver transplantation / M. Berenguer [et al.] // Hepatology. – 2000. – V. 32, № 4. – P. 852–858.Yilmaz, N. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation / N. Yilmaz [et al.] // Liver Transpl. – 2007. – V. 13. – P. 975–983.Yilmaz, N. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation / N. Yilmaz [et al.] // Liver Transpl. – 2007. – V. 13. – P. 975–983.Berenguer, M. Recurrent hepatitis C: worse outcomes established, interventions still inadequate / M. Berenguer // Liver Transpl. – 2007. – V. 13. – P. 641–643.Berenguer, M. Recurrent hepatitis C: worse outcomes established, interventions still inadequate / M. Berenguer // Liver Transpl. – 2007. – V. 13. – P. 641–643.Roche, B. Hepatitis C virus treatment pre- and post-liver transplantation / B. Roche, D. Samuel // Liver Int. – 2012. – V. 32, Suppl. 1. – P. 120–128.Roche, B. Hepatitis C virus treatment pre- and post-liver transplantation / B. Roche, D. Samuel // Liver Int. – 2012. – V. 32, Suppl. 1. – P. 120–128.Terrault, N.A. Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation / N.A. Terrault // Liver Transp1. – 2003. – V. 9, № 11, Suppl. 3. – P. S95–S100.Terrault, N.A. Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation / N.A. Terrault // Liver Transp1. – 2003. – V. 9, № 11, Suppl. 3. – P. S95–S100.Berenguer, M. Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation / M. Berenguer, [et al.] // Liver Int. – 2012. – V. 32, № 5. – P. 712–731.Berenguer, M. Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation / M. Berenguer, [et al.] // Liver Int. – 2012. – V. 32, № 5. – P. 712–731.Roche, B. Is early antiviral therapy for recurrent hepatitis C after liver transplantation superior to later treatment? The answer is no / B. Roche, D. Samuel // Liver Transplantation. – 2011. – V. 17, № 5. – P. 488–491.Roche, B. Is early antiviral therapy for recurrent hepatitis C after liver transplantation superior to later treatment? The answer is no / B. Roche, D. Samuel // Liver Transplantation. – 2011. – V. 17, № 5. – P. 488–491.Wang, C.S. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis / C.S. Wang [et al.] // American Journal of Transplantation. – 2006. – V. 6. – P. 1586–1599.Wang, C.S. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis / C.S. Wang [et al.] // American Journal of Transplantation. – 2006. – V. 6. – P. 1586–1599.Watt, K. A practical guide to the management of HCV infection following liver transplantation / K. Watt, B. Veldt, M. Charlton // American Journal of Transplantation. – 2009. – V. 9. – P. 1707–1713.Watt, K. A practical guide to the management of HCV infection following liver transplantation / K. Watt, B. Veldt, M. Charlton // American Journal of Transplantation. – 2009. – V. 9. – P. 1707–1713.Dinges, S. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation / S. Dinges [et al.] // Transpl. Infect. Dis. – 2009. – V. 11. – P. 33–39.Dinges, S. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation / S. Dinges [et al.] // Transpl. Infect. Dis. – 2009. – V. 11. – P. 33–39.Sharma, P. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence / P. Sharma [et al.] // Liver Transpl. – 2007. – V. 13. – P. 1100–1108.Sharma, P. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence / P. Sharma [et al.] // Liver Transpl. – 2007. – V. 13. – P. 1100–1108.Otona, E. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose peg- interferon and ribavirin / E. Otona [et al.] // American Journal of Transplantation. – 2006. – V. 6. – P. 2348–2355.Otona, E. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose peg- interferon and ribavirin / E. Otona [et al.] // American Journal of Transplantation. – 2006. – V. 6. – P. 2348–2355.Gonzalez, S.A. Management of recurrent hepatitis C following liver transplantation / S.A. Gonzalez // Gastroenterology & Hepatology. – 2010. – V. 6, Issue 10. – P. 637–645.Gonzalez, S.A. Management of recurrent hepatitis C following liver transplantation / S.A. Gonzalez // Gastroenterology & Hepatology. – 2010. – V. 6, Issue 10. – P. 637–645.Terrault, N.A. Treating hepatitis C infection in liver transplant recipients / N.A. Terrault, M. Berenguer // Liver Transpl. – 2006. – V. 12. – P. 1192–1204.Terrault, N.A. Treating hepatitis C infection in liver transplant recipients / N.A. Terrault, M. Berenguer // Liver Transpl. – 2006. – V. 12. – P. 1192–1204.

The authors declare that there are no conflicts of interest present.